GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Asset Turnover

Pulse Biosciences (Pulse Biosciences) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Pulse Biosciences's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Pulse Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $62.55 Mil. Therefore, Pulse Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Pulse Biosciences's annualized ROE % for the quarter that ended in Dec. 2023 was -98.92%. It is also linked to ROA % through Du Pont Formula. Pulse Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 was -76.31%.


Pulse Biosciences Asset Turnover Historical Data

The historical data trend for Pulse Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Asset Turnover Chart

Pulse Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.03 0.01 -

Pulse Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pulse Biosciences's Asset Turnover

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulse Biosciences's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's Asset Turnover falls into.



Pulse Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Pulse Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (77.877+59.154)/ 2 )
=0/68.5155
=0.00

Pulse Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (65.945+59.154)/ 2 )
=0/62.5495
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Pulse Biosciences  (NAS:PLSE) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Pulse Biosciences's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-47.732/48.2525
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-47.732 / 0)*(0 / 62.5495)*(62.5495/ 48.2525)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.2963
=ROA %*Equity Multiplier
=-76.31 %*1.2963
=-98.92 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Pulse Biosciences's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-47.732/62.5495
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-47.732 / 0)*(0 / 62.5495)
=Net Margin %*Asset Turnover
= %*0
=-76.31 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Pulse Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences (Pulse Biosciences) Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Executives
Robert W Duggan director, 10 percent owner 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy officer: Chief Commercial Officer 50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson director 3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner officer: CFO & EVP Admin. and Finance CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray director C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono director
Ed Ebbers officer: EVP & GM, Dermatology 3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D director C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg director 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow officer: CFO & SVP Admin. and Finance 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588